| HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.Lancet HIV | PMID 39008999无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.EBioMedicine | PMID 39018755PMC11287012 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.Expert Rev Respir Med | PMID 39106052无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.ESMO Open | PMID 39121814PMC11362642 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.Mult Scler | PMID 39143826无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.Health Technol Assess | PMID 39250424PMC11403377 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL).PLoS Med | PMID 39137167PMC11321588 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan® (Pfizer) in patients with ocular hypertension or primary open-angle glaucoma.BMC Ophthalmol | PMID 39075412PMC11285291 | 2024-Jul-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.Arthritis Res Ther | PMID 39075620PMC11285135 | 2024-Jul-29 | 0.85 | The study is a randomized Phase 3 trial of a drug intervention with original results, but it is for rheumatoid arthritis, not human malignant neoplasm (oncology). It also lacks the required time-to-event efficacy endpoint. | 待处理 |
| Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.Lancet | PMID 38971175无 PMCID | 2024-Jul-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial.Lancet | PMID 38991582无 PMCID | 2024-Jul-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: An open-label, randomized, comparative, multicenter study.Medicine (Baltimore) | PMID 39058806PMC11272322 | 2024-Jul-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.BMC Cancer | PMID 39060961PMC11282593 | 2024-Jul-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.BMC Cancer | PMID 39054462PMC11270757 | 2024-Jul-25 | 0.97 | 仅有 Phase I/II 证据,未达到确证性随机试验标准。 | 待处理 |
| Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.Vaccine | PMID 38762360PMC11252665 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.N Engl J Med | PMID 39047240PMC11334054 | 2024-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.J Infect Dis | PMID 39052718PMC11272042 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.J Infect Dis | PMID 39052726PMC11272088 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.J Infect Dis | PMID 39052734PMC11272062 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.J Infect Dis | PMID 39052748PMC11272083 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).BMC Cancer | PMID 39054430PMC11270760 | 2024-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.BMC Cancer | PMID 39054467PMC11270762 | 2024-Jul-25 | 0.95 | While this is a phase III randomized trial with drug interventions reporting original results, it does not meet the required time-to-event endpoint criterion. The primary endpoint was ORR (objective response rate), a binary measure, and the secondary endpoints were safety/tolerability and an exploratory pharmacodynamic endpoint. No survival or progression-free survival endpoints (which are time-to-event outcomes) were reported or analyzed in this publication. The deterministic review signal 'no_time_to_event_signal' is confirmed. | 待处理 |
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.BMC Cancer | PMID 39054485PMC11270759 | 2024-Jul-25 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.BMC Cancer | PMID 39054491PMC11270764 | 2024-Jul-25 | 0.95 | The study is an eligible randomized Phase III trial in oncology with a drug intervention, but the primary endpoint is ORR, not a time-to-event outcome. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.RMD Open | PMID 39059811PMC11284939 | 2024-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial.Nat Commun | PMID 39048547PMC11269576 | 2024-Jul-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Development and application of a qualitative rapid analysis framework in a hybrid trial within primary care.BMJ Open | PMID 39053958PMC11284935 | 2024-Jul-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).J Clin Oncol | PMID 38709986PMC11513887 | 2024-Jul-20 | 0.95 | This is a Phase III randomized, placebo-controlled trial in breast cancer survivors with a drug intervention, but it lacks a primary or key secondary time-to-event efficacy endpoint. The primary outcome is cognitive function (HVLT-R score) analyzed with mixed-effects repeated measures ANCOVA, not a survival or time-to-event outcome. Therefore, it does not meet the criterion for a time-to-event endpoint required for KM digitization. | 待处理 |
| CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.J Clin Oncol | PMID 38828957PMC11268557 | 2024-Jul-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.Clin Exp Dermatol | PMID 37820029无 PMCID | 2024-Jul-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.N Engl J Med | PMID 38884324无 PMCID | 2024-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.N Engl J Med | PMID 39018531无 PMCID | 2024-Jul-18 | 0.95 | The study is a Phase 3 randomized trial of drug interventions for Crohn's disease, not a human malignant neoplasm. It does not meet the core oncology eligibility criterion. | 待处理 |
| Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.N Engl J Med | PMID 39018532PMC11694828 | 2024-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Entomological effects of attractive targeted sugar bait station deployment in Western Zambia: vector surveillance findings from a two-arm cluster randomized phase III trial.Malar J | PMID 39026236PMC11264679 | 2024-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial.J Natl Compr Canc Netw | PMID 39019060无 PMCID | 2024-Jul-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.Br J Dermatol | PMID 38629497无 PMCID | 2024-Jul-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.Int J Radiat Oncol Biol Phys | PMID 38218455无 PMCID | 2024-Jul-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.Ann Rheum Dis | PMID 38569851PMC12056589 | 2024-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.RMD Open | PMID 39004432PMC11253752 | 2024-Jul-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Pharmacogenomics J | PMID 38992025PMC11374128 | 2024-Jul-12 | 0.80 | The report is from a Phase III RCT in cancer patients, but its primary and reported outcome is the risk of a specific adverse event (hypertension), not the survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for inclusion in this cohort. | 待处理 |
| CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.J Clin Oncol | PMID 38552197PMC11227305 | 2024-Jul-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.J Clin Oncol | PMID 38710003PMC11227300 | 2024-Jul-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.J Clin Oncol | PMID 38759121PMC11377096 | 2024-Jul-10 | 0.95 | The study is an eligible Phase III randomized trial with a time-to-event endpoint, but the intervention is radiotherapy alone, not a drug-containing intervention. It does not meet the inclusion criterion for a drug-containing intervention. | 待处理 |
| Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.Antimicrob Agents Chemother | PMID 38780262PMC11232400 | 2024-Jul-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Deployment of attractive targeted sugar baits in western Zambia: installation, monitoring, removal, and disposal procedures during a Phase III cluster randomized controlled trial.Malar J | PMID 38982496PMC11234656 | 2024-Jul-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).Mod Rheumatol | PMID 37606691无 PMCID | 2024-Jul-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.Lancet | PMID 38876133无 PMCID | 2024-Jul-06 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.Oncologist | PMID 38394384PMC11224990 | 2024-Jul-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.Blood | PMID 38643510PMC11251404 | 2024-Jul-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Donidalorsen for Hereditary Angioedema.N Engl J Med | PMID 38819395无 PMCID | 2024-Jul-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |